Background Transradial coronary intervention has been widely used because of its effects in lowering the incidence of complications in vascular access site and improving patient satisfaction compared to the femoral ap...Background Transradial coronary intervention has been widely used because of its effects in lowering the incidence of complications in vascular access site and improving patient satisfaction compared to the femoral approach. This study aimed to investigate the safety and feasibility of transradial approach for primary percutaneous coronary intervention （PCI） in elderly patients with acute myocardial infarction （AMI）. Methods A total of 103 consecutive elderly patients Cage 〉65 years） who were diagnosed as having AMI were indicated for PCI. Among them, 57 patients received primary PCI via the transradial approach （transradial intervention, TRI group）, and 46 underwent primary PCI via the transfemoral approach （transfemoral intervention, TFI group）. The success rate of puncture, puncture time, cannulation time, repeffusion time, the total time for PCI, the success rate of PCI, the use rates of temporary pacemaker and intra-aortic balloon pump （IABP）, and the total length of hospital stay of the patients in the two groups were compared. After the procedure, vascular access site complications and major adverse cardiovascular events （MACE） in the two groups in one month were observed. Results The success rates of puncture （98.2% vs 100.0%） and PCI （96.5% vs 95.7%） for the patients in the TRI and TFI groups were not statistically significant （P〉0.05）. The puncture time （（2.4±1.1） vs （2.0±0.9） minutes）, cannulation time （（2.7±0.5） vs （2.6±0.5） minutes）, reperfusion time （（16.2±4.5） vs （15.4±3.6） minutes）, total time of the procedure （（44.1±6.8） vs （41.2±5.7） minutes）, use rates of temporary pacemaker （1.8% vs 2.2%） and IABP （0 vs 2.2%） in the two groups were not statistically significant （P〉0.05）, but the hospital stay of the TFI group was longer than that of the TRI group （（10.1±4.6） vs （7.2±2..6） days, P〈0.01）. A radial occlusion was observed in the TRI group, but no ischemic syndrome in hand展开更多
目的探讨依达拉奉联合阿替普酶对老年急性脑梗死(acute cerebral infarction,ACI)患者脑血流及神经损伤的影响。方法随机将105例老年ACI患者分为常规治疗组(n=52)和联合治疗组(n=53)。常规治疗组采用阿替普酶治疗,联合治疗组在常规治疗...目的探讨依达拉奉联合阿替普酶对老年急性脑梗死(acute cerebral infarction,ACI)患者脑血流及神经损伤的影响。方法随机将105例老年ACI患者分为常规治疗组(n=52)和联合治疗组(n=53)。常规治疗组采用阿替普酶治疗,联合治疗组在常规治疗组基础上采用依达拉奉治疗。采用经颅多普勒超声检查测定双侧大脑中动脉的平均流速(Vm)和峰流速(Vp)水平。参照美国国立卫生研究院卒中量表(the national institutes of health stroke scale,NIHSS)、简易健康状况量表(short form-36,SF-36)标准评价神经损伤程度和生活质量。结果经治疗后,联合治疗组治疗总有效率较常规治疗组明显增高,Vm、Vp、SF-36评分较治疗前和常规治疗组相应值明显升高,NIHSS评分较治疗前和常规治疗组相应值明显降低(P<0.05)。2组药物不良反应率比较差异无统计学意义(P>0.05)。结论依达拉奉联合阿替普酶可有效安全应用于老年ACI患者的治疗期间,可明显改善脑血流动力学,降低神经损伤程度,值得临床推广应用。展开更多
目的:观察银杏叶提取物制剂序贯疗法治疗老年急性脑梗死的临床效果和安全性,并进行药物经济学评价。方法:选取2014年8月-2015年8月我院神经内科收治的急性脑梗死患者98例,按随机数字表法分为对照组和试验组,各49例。两组患者均进行抗血...目的:观察银杏叶提取物制剂序贯疗法治疗老年急性脑梗死的临床效果和安全性,并进行药物经济学评价。方法:选取2014年8月-2015年8月我院神经内科收治的急性脑梗死患者98例,按随机数字表法分为对照组和试验组,各49例。两组患者均进行抗血小板聚集、改善微循环等常规治疗;对照组患者在常规治疗基础上给予舒血宁注射液10 m L,ivgtt,qd,连用21 d;试验组患者在常规治疗基础上给予舒血宁注射液10 m L,ivgtt,qd,7~10 d后停用,改用银杏叶片1片,po,tid,累计用药21 d。比较两组患者的临床疗效,治疗前后的欧洲脑卒中量表(ESS)评分、日常生活活动能力量表(ADL)评分、血液流变学指标和血脂指标,以及不良反应发生情况,并用最小成本分析法进行药物经济学评价。结果:治疗后,对照组、试验组患者的总有效率分别为87.23%、83.33%,两组比较差异无统计学意义(P>0.05)。治疗前,两组患者的ESS评分、ADL评分、血液流变学和血脂指标比较,差异均无统计学意义(P>0.05);治疗后,两组患者的ESS和ADL评分均明显升高,全血黏度、血浆黏度、血细胞比容、纤维蛋白原含量、TC和TG均明显降低,与治疗前比较差异均有统计学意义(P<0.05),但组间比较差异均无统计学意义(P>0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。对照组和试验组的平均治疗成本分别为(7 060.9±234.8)元和(5 800.7±149.5)元,差异有统计学意义(P<0.01)。结论:银杏叶提取物制剂序贯疗法与静脉滴注给药治疗老年急性脑梗死的疗效、安全性相当,但序贯疗法更具经济学优势。展开更多
文摘Background Transradial coronary intervention has been widely used because of its effects in lowering the incidence of complications in vascular access site and improving patient satisfaction compared to the femoral approach. This study aimed to investigate the safety and feasibility of transradial approach for primary percutaneous coronary intervention （PCI） in elderly patients with acute myocardial infarction （AMI）. Methods A total of 103 consecutive elderly patients Cage 〉65 years） who were diagnosed as having AMI were indicated for PCI. Among them, 57 patients received primary PCI via the transradial approach （transradial intervention, TRI group）, and 46 underwent primary PCI via the transfemoral approach （transfemoral intervention, TFI group）. The success rate of puncture, puncture time, cannulation time, repeffusion time, the total time for PCI, the success rate of PCI, the use rates of temporary pacemaker and intra-aortic balloon pump （IABP）, and the total length of hospital stay of the patients in the two groups were compared. After the procedure, vascular access site complications and major adverse cardiovascular events （MACE） in the two groups in one month were observed. Results The success rates of puncture （98.2% vs 100.0%） and PCI （96.5% vs 95.7%） for the patients in the TRI and TFI groups were not statistically significant （P〉0.05）. The puncture time （（2.4±1.1） vs （2.0±0.9） minutes）, cannulation time （（2.7±0.5） vs （2.6±0.5） minutes）, reperfusion time （（16.2±4.5） vs （15.4±3.6） minutes）, total time of the procedure （（44.1±6.8） vs （41.2±5.7） minutes）, use rates of temporary pacemaker （1.8% vs 2.2%） and IABP （0 vs 2.2%） in the two groups were not statistically significant （P〉0.05）, but the hospital stay of the TFI group was longer than that of the TRI group （（10.1±4.6） vs （7.2±2..6） days, P〈0.01）. A radial occlusion was observed in the TRI group, but no ischemic syndrome in hand
文摘目的探讨依达拉奉联合阿替普酶对老年急性脑梗死(acute cerebral infarction,ACI)患者脑血流及神经损伤的影响。方法随机将105例老年ACI患者分为常规治疗组(n=52)和联合治疗组(n=53)。常规治疗组采用阿替普酶治疗,联合治疗组在常规治疗组基础上采用依达拉奉治疗。采用经颅多普勒超声检查测定双侧大脑中动脉的平均流速(Vm)和峰流速(Vp)水平。参照美国国立卫生研究院卒中量表(the national institutes of health stroke scale,NIHSS)、简易健康状况量表(short form-36,SF-36)标准评价神经损伤程度和生活质量。结果经治疗后,联合治疗组治疗总有效率较常规治疗组明显增高,Vm、Vp、SF-36评分较治疗前和常规治疗组相应值明显升高,NIHSS评分较治疗前和常规治疗组相应值明显降低(P<0.05)。2组药物不良反应率比较差异无统计学意义(P>0.05)。结论依达拉奉联合阿替普酶可有效安全应用于老年ACI患者的治疗期间,可明显改善脑血流动力学,降低神经损伤程度,值得临床推广应用。
文摘目的:观察银杏叶提取物制剂序贯疗法治疗老年急性脑梗死的临床效果和安全性,并进行药物经济学评价。方法:选取2014年8月-2015年8月我院神经内科收治的急性脑梗死患者98例,按随机数字表法分为对照组和试验组,各49例。两组患者均进行抗血小板聚集、改善微循环等常规治疗;对照组患者在常规治疗基础上给予舒血宁注射液10 m L,ivgtt,qd,连用21 d;试验组患者在常规治疗基础上给予舒血宁注射液10 m L,ivgtt,qd,7~10 d后停用,改用银杏叶片1片,po,tid,累计用药21 d。比较两组患者的临床疗效,治疗前后的欧洲脑卒中量表(ESS)评分、日常生活活动能力量表(ADL)评分、血液流变学指标和血脂指标,以及不良反应发生情况,并用最小成本分析法进行药物经济学评价。结果:治疗后,对照组、试验组患者的总有效率分别为87.23%、83.33%,两组比较差异无统计学意义(P>0.05)。治疗前,两组患者的ESS评分、ADL评分、血液流变学和血脂指标比较,差异均无统计学意义(P>0.05);治疗后,两组患者的ESS和ADL评分均明显升高,全血黏度、血浆黏度、血细胞比容、纤维蛋白原含量、TC和TG均明显降低,与治疗前比较差异均有统计学意义(P<0.05),但组间比较差异均无统计学意义(P>0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。对照组和试验组的平均治疗成本分别为(7 060.9±234.8)元和(5 800.7±149.5)元,差异有统计学意义(P<0.01)。结论:银杏叶提取物制剂序贯疗法与静脉滴注给药治疗老年急性脑梗死的疗效、安全性相当,但序贯疗法更具经济学优势。
